Background
Phase 2, multicenter, open-label, randomized (1:1) trial at 4 academic hospitals in China. N=125. Untreated, resectable stage III–IVB HNSCC; 82% oral cavity primaries. Tests perioperative anti-PD-1 chemoimmunotherapy (neoadjuvant + adjuvant + maintenance camrelizumab) vs upfront surgery.
Results
Interventions and follow up: Arm A: camrelizumab 200 mg + nab-paclitaxel + carboplatin q3w x2 neoadjuvant → surgery → risk-adapted adjuvant therapy → maintenance camrelizumab up to 15 cycles (n=63)
Arm B: upfront surgery → standard risk-adapted adjuvant (chemo)radiotherapy (n=62)
Primary endpoint: 2-year EFS
mFollow up: 24.6 mo
Results: 2-yr EFS: 77.8% vs 46.1%; HR 0.34 (0.17–0.68); P=.001
2-yr OS: 92.0% vs 69.1%; HR 0.25 (0.10–0.64)
2-yr DMFS: HR 0.15 (0.03–0.68)
MPR: 47.6% vs 0%
pCR: 25.4% vs 0%
Arm B: upfront surgery → standard risk-adapted adjuvant (chemo)radiotherapy (n=62)
Primary endpoint: 2-year EFS
mFollow up: 24.6 mo
Results: 2-yr EFS: 77.8% vs 46.1%; HR 0.34 (0.17–0.68); P=.001
2-yr OS: 92.0% vs 69.1%; HR 0.25 (0.10–0.64)
2-yr DMFS: HR 0.15 (0.03–0.68)
MPR: 47.6% vs 0%
pCR: 25.4% vs 0%
Adverse events
Grade ≥3 TEAEs: 79.4% vs 56.5%
Fatal TEAEs: 0 vs 1
Discontinuation: NR in abstract
Fatal TEAEs: 0 vs 1
Discontinuation: NR in abstract
Conclusions
Perioperative camrelizumab plus nab-paclitaxel/carboplatin more than halved the risk of EFS events versus upfront surgery in resectable locally advanced HNSCC, with an apparent OS benefit. The magnitude of effect supports intensified perioperative immune priming but requires phase 3 confirmation.
Key Limitations
Small phase 2 trial (n=125) at 4 centers in China; open-label. Control-arm 2-yr EFS of 46% is low for resectable HNSCC, which may inflate the effect size. OS is a secondary endpoint with few events and wide CIs. Experimental arm adds neoadjuvant chemotherapy, which itself has not improved survival in prior HNSCC trials, so the PD-1 contribution cannot be isolated. Oral-cavity-predominant population; camrelizumab not available in the US/EU. Higher grade ≥3 toxicity (79% vs 57%).
Clinical Context
Standard for resectable locally advanced HNSCC is surgery followed by risk-adapted adjuvant RT or CRT. KEYNOTE-689 (neoadjuvant + adjuvant pembrolizumab, without neoadjuvant chemo) established perioperative immunotherapy, and pembrolizumab is FDA-approved in this setting for PD-L1 CPS ≥1. CAMORAL adds signal for a neoadjuvant chemoimmunotherapy approach; camrelizumab has no FDA/EMA approval.
